SCHEMBL29677574

SCHEMBL29677574

C#CCOCCOCCOCCOCCNC(=O)CC[C@H](NC(=O)OC(C)(C)C)c1nn[nH]n1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NAALAD2 Q9Y3Q0 1/20 0.40
GRN P28799 1/20 0.33
SORT1 Q99523 1/20 0.33
PLK1 P53350 2/20 0.32
ADORA1 P30542 1/20 0.31
PSEN1 P49768 2/20 0.31
PSEN2 P49810 2/20 0.31
APH1B Q8WW43 2/20 0.31
NCSTN Q92542 2/20 0.31
APH1A Q96BI3 2/20 0.31
PSENEN Q9NZ42 2/20 0.31
DDAH1 O94760 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
MAPT P10636 1/20 0.31
GBA1 P04062 1/20 0.30
ALDH1A1 P00352 1/20 0.30
BCHE P06276 1/20 0.30
ACHE P22303 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30097269 0.86 NAALAD2 (0.35) NAALAD2
SCHEMBL29677931 0.81 DDAH1 (0.43) NAALAD2DDAH1MEN1KMT2AMAPT
SCHEMBL24629285 0.77 CAPN1 (0.36) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL29677972 0.76 NAALAD2 (0.69) NAALAD2GRNSORT1MEN1KMT2A
SCHEMBL23789774 0.74 TDP1 (0.39) PLK1ADORA1MEN1KMT2ABCHE
SCHEMBL19451119 0.74 TDP1 (0.39) PLK1ADORA1MEN1KMT2ABCHE
SCHEMBL24810240 0.72 CA1 (0.45) PLK1MEN1KMT2A
SCHEMBL18237306 0.72 LTA4H (0.39) PLK1MEN1KMT2AALDH1A1
SCHEMBL30097254 0.72 LTA4H (0.39) PLK1MEN1KMT2AALDH1A1
SCHEMBL19451386 0.71 TDP1 (0.45) MEN1KMT2ABCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127913-A1 BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS LYCIA THERAPEUTICS, INC. 2025-04-24 US disclosed
US-20240165250-A1 Bifunctional Folate Receptor Binding Compounds LYCIA THERAPEUTICS, INC. 2024-05-23 US disclosed
EP-4359414-A1 BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS Lycia Therapeutics, Inc. (US) 2024-05-01 EP disclosed
EP-4274619-A1 BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS Lycia Therapeutics, Inc. (US) 2023-11-15 EP disclosed
WO-2022272307-A1 BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS LYCIA THERAPEUTICS, INC. (US) 2022-12-29 WO disclosed
WO-2022150721-A1 BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS LYCIA THERAPEUTICS, INC. (US) 2022-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250127913-A1 BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS FOLR1, FOLR2, FOLH1 NAALAD2 344/4885GRN 2473/4885SORT1 176/4885
US-20240165250-A1 Bifunctional Folate Receptor Binding Compounds FOLR1, FOLR2, FOLH1 NAALAD2 344/4885GRN 2473/4885SORT1 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.